255 related articles for article (PubMed ID: 14532275)
21. Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.
Fabre B; Ramos A; de Pascual-Teresa B
J Med Chem; 2014 Dec; 57(24):10205-19. PubMed ID: 25265401
[TBL] [Abstract][Full Text] [Related]
22. Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes.
Chen L; Rydel TJ; Gu F; Dunaway CM; Pikul S; Dunham KM; Barnett BL
J Mol Biol; 1999 Oct; 293(3):545-57. PubMed ID: 10543949
[TBL] [Abstract][Full Text] [Related]
23. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.
Fernandez-Catalan C; Bode W; Huber R; Turk D; Calvete JJ; Lichte A; Tschesche H; Maskos K
EMBO J; 1998 Sep; 17(17):5238-48. PubMed ID: 9724659
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and evaluation of matrix metalloprotease inhibitors bearing cyclopropane-derived peptidomimetics as P1' and P2' replacements.
Reichelt A; Gaul C; Frey RR; Kennedy A; Martin SF
J Org Chem; 2002 Jun; 67(12):4062-75. PubMed ID: 12054939
[TBL] [Abstract][Full Text] [Related]
26. Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses.
Eckhard U; Huesgen PF; Schilling O; Bellac CL; Butler GS; Cox JH; Dufour A; Goebeler V; Kappelhoff R; Keller UAD; Klein T; Lange PF; Marino G; Morrison CJ; Prudova A; Rodriguez D; Starr AE; Wang Y; Overall CM
Matrix Biol; 2016 Jan; 49():37-60. PubMed ID: 26407638
[TBL] [Abstract][Full Text] [Related]
27. Molecular Dynamics Simulations of Matrix Metalloproteinase 13 and the Analysis of the Specificity Loop and the S1'-Site.
Choi JY; Chung E
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445757
[TBL] [Abstract][Full Text] [Related]
28. The 1.8-A crystal structure of a matrix metalloproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition.
Brandstetter H; Grams F; Glitz D; Lang A; Huber R; Bode W; Krell HW; Engh RA
J Biol Chem; 2001 May; 276(20):17405-12. PubMed ID: 11278347
[TBL] [Abstract][Full Text] [Related]
29. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
30. Probing the S1/S1' substrate binding pocket geometry of HIV-1 protease with modified aspartic acid analogues.
Short GF; Laikhter AL; Lodder M; Shayo Y; Arslan T; Hecht SM
Biochemistry; 2000 Aug; 39(30):8768-81. PubMed ID: 10913288
[TBL] [Abstract][Full Text] [Related]
31. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor.
Rowsell S; Hawtin P; Minshull CA; Jepson H; Brockbank SM; Barratt DG; Slater AM; McPheat WL; Waterson D; Henney AM; Pauptit RA
J Mol Biol; 2002 May; 319(1):173-81. PubMed ID: 12051944
[TBL] [Abstract][Full Text] [Related]
32. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach.
Terp GE; Cruciani G; Christensen IT; Jørgensen FS
J Med Chem; 2002 Jun; 45(13):2675-84. PubMed ID: 12061871
[TBL] [Abstract][Full Text] [Related]
33. Structural basis for the highly selective inhibition of MMP-13.
Engel CK; Pirard B; Schimanski S; Kirsch R; Habermann J; Klingler O; Schlotte V; Weithmann KU; Wendt KU
Chem Biol; 2005 Feb; 12(2):181-9. PubMed ID: 15734645
[TBL] [Abstract][Full Text] [Related]
34. Structure analysis reveals the flexibility of the ADAMTS-5 active site.
Shieh HS; Tomasselli AG; Mathis KJ; Schnute ME; Woodard SS; Caspers N; Williams JM; Kiefer JR; Munie G; Wittwer A; Malfait AM; Tortorella MD
Protein Sci; 2011 Apr; 20(4):735-44. PubMed ID: 21370305
[TBL] [Abstract][Full Text] [Related]
35. Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.
Lockbaum GJ; Leidner F; Rusere LN; Henes M; Kosovrasti K; Nachum GS; Nalivaika EA; Ali A; Yilmaz NK; Schiffer CA
ACS Infect Dis; 2019 Feb; 5(2):316-325. PubMed ID: 30543749
[TBL] [Abstract][Full Text] [Related]
36. Solution structure of the catalytic domain of human collagenase-3 (MMP-13) complexed to a potent non-peptidic sulfonamide inhibitor: binding comparison with stromelysin-1 and collagenase-1.
Zhang X; Gonnella NC; Koehn J; Pathak N; Ganu V; Melton R; Parker D; Hu SI; Nam KY
J Mol Biol; 2000 Aug; 301(2):513-24. PubMed ID: 10926524
[TBL] [Abstract][Full Text] [Related]
37. Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.
Jin Y; Roycik MD; Bosco DB; Cao Q; Constantino MH; Schwartz MA; Sang QX
J Med Chem; 2013 Jun; 56(11):4357-73. PubMed ID: 23631440
[TBL] [Abstract][Full Text] [Related]
38. [Design, synthesis and activity evaluation of novel matrix metalloproteinases inhibitors based on the structure of enzyme].
Jia H; Guo YS; Ge YY; Wen H; Yang J; Yang XY; Du GH; Yang GZ
Yao Xue Xue Bao; 2007 Dec; 42(12):1271-81. PubMed ID: 18338640
[TBL] [Abstract][Full Text] [Related]
39. Engineering of selective TIMPs.
Nagase H; Meng Q; Malinovskii V; Huang W; Chung L; Bode W; Maskos K; Brew K
Ann N Y Acad Sci; 1999 Jun; 878():1-11. PubMed ID: 10415716
[TBL] [Abstract][Full Text] [Related]
40. Impact of mobility on structure-based drug design for the MMPs.
Moy FJ; Chanda PK; Chen J; Cosmi S; Edris W; Levin JI; Rush TS; Wilhelm J; Powers R
J Am Chem Soc; 2002 Oct; 124(43):12658-9. PubMed ID: 12392402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
